Cefoperazone Sodium and Tazobactam Sodium for Injection

Pharmacological action: The main ingredients of this compound are cefoperazone and tazobactam. Cefoperazone is a third-generation cephalosporin that achieves its bactericidal effect by inhibiting the biosynthesis of the cell wall of sensitive bacteria. Tazobactam has no antibacterial activity against other bacteria except Neisseriaceae and Acinetobacter, but it has an irreversible inhibitory effect on most important β-lactamases produced by β-lactam antibiotic-resistant strains. Therefore, tazobactam can prevent the destruction of penicillins and cephalosporins by related resistant bacteria, reflecting that tazobactam has a certain synergistic effect with penicillins and cephalosporins. Since tazobactam can bind to certain penicillin-binding proteins, sensitive strains may be more sensitive to this compound preparation than when cefoperazone is used alone. <

Each antibiotic bottle contains 0.8g of cefoperazone sodium (calculated as cefoperazone) and 0.2g of tazobactam sodium (calculated as tazobactam).

It is suitable for moderate and severe infections caused by pathogens that produce or do not produce lactamase that are sensitive to this product: respiratory tract infections: pneumonia, acute exacerbation of chronic bronchitis, acute bronchitis, lung abscess and other lung infections; urinary tract infections: acute pyelonephritis, acute exacerbation of chronic pyelonephritis, complicated urinary tract infection; abdominal infections: peritonitis, cholecystitis, cholangitis and other intra-abdominal infections; pelvic infections: pelvic inflammatory disease, etc.; reproductive system infections: endometritis, gonorrhea and other reproductive tract infections; other infections: sepsis, meningitis, skin and soft tissue infections, etc.

Intravenous drip. First dissolve with an appropriate amount of sodium chloride injection or sterile water for injection (5-10ml), then add 5% glucose injection or sodium chloride injection 150-250ml to dilute for intravenous drip, the drip time is 30-60 minutes, and each drip time must not be less than 30 minutes. The course of treatment is generally 7-10 days (severe infection can be appropriately extended). Adult dosage: 1.125-2.25g/time, intravenous drip once every 8 hours or 12 hours. For patients with severe renal insufficiency (creatinine elimination rate <30ml/min), the dose of tazobactam should not exceed 0.5g every 12 hours.

Patients usually tolerate this product well, and most adverse reactions are mild and disappear after drug discontinuation. 1. Gastrointestinal tract: As with other β-lactam antibiotics, common side effects of this product are gastrointestinal reactions; the most common are loose stools and diarrhea, followed by nausea and vomiting. 2. Skin reactions: This product may cause allergic reactions, manifested as maculopapular rash, urticaria, eosinophilia and drug fever. 3. Blood: Long-term use of this product may lead to reversible neutropenia, thrombocytopenia, prolonged prothrombin time, and decreased prothrombin activity, which can be seen in individual cases. Bleeding is rare and can be prevented and controlled with vitamin K. 4. Laboratory abnormalities: A few cases have aspartate transaminase

1. It is contraindicated for those who are allergic to any ingredient of this product or other β-lactam antibiotics; 2. It is used with caution by pregnant and lactating women.

Precautions during pregnancy and lactation: Use with caution in pregnant and lactating women.

1 When used in combination with aminoglycoside antibiotics (gentamicin and tobramycin), it has a synergistic effect against certain sensitive strains of Enterobacteriaceae and Pseudomonas aeruginosa. However, there are physical incompatibility between this product and aminoglycoside antibiotics, so the two liquids cannot be directly mixed. If combined use is required, the two drugs can be injected intravenously in sequence. Different intravenous infusion lines should be used for injection, or the previously used intravenous infusion line should be fully flushed with another approved diluent between injections. In addition, the interval between the administration of the two drugs should be extended as much as possible. 2 Bleeding may occur when used simultaneously with the following drugs: anticoagulants heparin, coumarin or indandione derivatives, thrombolytics, non-steroidal anti-inflammatory analgesics (especially a

Sealed and stored in a cool place. Validity period: 24 months

1.0 g (cefoperazone 0.8 g and tazobactam 0.2 g)